<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100372</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000669716</org_study_id>
    <secondary_id>MUI-AGO-10</secondary_id>
    <secondary_id>EUDRACT-2008-008746-20</secondary_id>
    <secondary_id>EU-21028</secondary_id>
    <nct_id>NCT01100372</nct_id>
  </id_info>
  <brief_title>Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer</brief_title>
  <official_title>Randomized Phase II AGO-Study Comparing Combined Liposomal Doxorubicin (Myocet) and Gemcitabine (Gemzar) With Liposomal Doxorubicin (Myocet) Monotherapy in Platinum-Refractory and Platinum-Resistant Epithelial Cancer of the Ovary, Fallopian Tube and the Peritoneum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as liposome-encapsulated doxorubicin citrate and&#xD;
      gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either&#xD;
      by killing the cells or by stopping them from dividing. It is not yet known whether&#xD;
      liposome-encapsulated doxorubicin citrate is more effective when given together with or&#xD;
      without gemcitabine hydrochloride in killing tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying liposome-encapsulated doxorubicin citrate&#xD;
      given together with gemcitabine hydrochloride to see how well it works compared with&#xD;
      liposome-encapsulated doxorubicin citrate alone in treating patients with ovarian epithelial&#xD;
      cancer, fallopian tube cancer, or primary peritoneal cavity cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the response rate to liposome-encapsulated doxorubicin citrate and gemcitabine&#xD;
           hydrochloride versus liposome-encapsulated doxorubicin citrate alone in patients with&#xD;
           platinum-refractory or platinum-resistant ovarian epithelial, fallopian tube, or primary&#xD;
           peritoneal cavity cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  To determine the progression-free and overall survival of patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  To determine the toxicity of these regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to disease&#xD;
      (platinum-refractory disease vs platinum-resistant disease. Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive liposome-encapsulated doxorubicin citrate IV over 60 minutes on&#xD;
           day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment&#xD;
           repeats every 3 weeks for 6 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive liposome-encapsulated doxorubicin citrate IV over 60 minutes on&#xD;
           day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Patients who experience clinical benefit after completion of 6 courses of chemotherapy may&#xD;
      continue therapy at the discretion of the investigator.&#xD;
&#xD;
      Patients complete quality-of-life questionnaires (EORTC-QLQ30 and QLQ-OV28) at baseline,&#xD;
      during, and after completion of study therapy. After completion of study treatment, patients&#xD;
      are followed up every 3 months for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rates (complete response and partial response)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by EORTC-QLQ30 and QLQ-OV28 questionnaires</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposome-encapsulated doxorubicin citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal&#xD;
             cavity cancer&#xD;
&#xD;
          -  Progression or recurrence during first-line platinum-based chemotherapy&#xD;
             (platinum-refractory disease) OR progression or recurrence during the first 6 months&#xD;
             following the end of the last platinum-containing chemotherapy (platinum-resistant&#xD;
             disease)&#xD;
&#xD;
          -  Meets ≥ 1 of the following criteria:&#xD;
&#xD;
               -  Measurable metastatic disease on CT or MRI scan, ultrasound, or chest x-ray&#xD;
&#xD;
               -  Evaluable disease on CT/MRI scan (e.g., ascites or pleural effusion) or chest&#xD;
                  x-ray (e.g., pleural effusion)&#xD;
&#xD;
               -  Tumor marker progression (CA-125) according to Rustin criteria, meeting 1 of the&#xD;
                  following criteria:&#xD;
&#xD;
                    -  CA-125 &gt; 2 times upper limit of normal (UNL)&#xD;
&#xD;
                    -  CA-125 &gt; 2 times nadir value on two occasions&#xD;
&#xD;
          -  No ovarian carcinosarcoma (malignant mixed Müllerian tumor) or pure sarcoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Neutrophil count ≥ 1.5 x 10³/mm³&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN (&lt; 2.5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  AST/ALT &lt; 2.5 times ULN (unless caused by parenchymal liver metastases)&#xD;
&#xD;
          -  No childbearing capacity&#xD;
&#xD;
          -  LVEF ≥ 50% by ECHO or MUGA scan&#xD;
&#xD;
          -  No significant comorbidity (e.g., uncontrolled infection, clinical signs of cardiac&#xD;
             insufficiency, history of myocardial infarction, or cardiac rhythmic disorders [NYHA&#xD;
             class III-IV disease])&#xD;
&#xD;
          -  No known hypersensitivity to study drugs&#xD;
&#xD;
          -  No active secondary malignant tumor within the past 5 years (e.g., metastases from&#xD;
             primary breast cancer)&#xD;
&#xD;
          -  No condition (medical, social, or psychological), that would prevent adequate&#xD;
             follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy with pegylated liposomal doxorubicin hydrochloride, other&#xD;
             anthracyclines, or gemcitabine hydrochloride&#xD;
&#xD;
          -  No other concurrent tumor-specific therapy for ovarian cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Zeimet</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Innsbruck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Innsbruck Universitaetsklinik</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>43-512-504-24155</phone>
      <email>Alain.zeimet@i-med.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2010</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent fallopian tube cancer</keyword>
  <keyword>recurrent primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

